Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy

The use of terminal complement blockade is compatible with virus-specific T-cell (VST) expansion and clinical effectiveness. VST and complement-blocking agent concurrent therapy may be safely used in patients with thrombotic microangiopathy and viral infections.

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Rubinstein, Jeremy D., Zhu, Xiang, Lutzko, Carolyn, Leemhuis, Tom, Cancelas, Jose A., Jodele, Sonata, Bollard, Catherine M., Hanley, Patrick J., Davies, Stella M., Grimley, Michael S., Nelson, Adam S.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Stimulus Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7391136/
https://ncbi.nlm.nih.gov/pubmed/32697816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002252
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars